Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Coley Pharmaceutical Group, Inc. (COLY) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/01/2007 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Third Quarter and Nine-month Financial Results"
08/02/2007 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Second Quarter and Six-month Financial Results Wellesley, MA, August 2, 2007 - Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, today reported financial results for the second quarter and six months ended June 30, 2007. FINANCIAL UPDATES"
05/03/2007 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports First Quarter Financial Results Wellesley, MA, May 3, 2007 - Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, today reported financial results for the first quarter of 2007. FINANCIAL UPDATES"
02/15/2007 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Fourth Quarter and Full Year 2006 Financial Results Wellesley, MA, February 15, 2007 - Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, today reported financial results for the fourth quarter and year ended December 31, 2006. The company also announced its annual corporate objectives and provided full-year 2007 financial guidance."
11/02/2006 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Third Quarter and Nine-month Financial and Operational Results Wellesley, MA, November 2, 2006 - Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, today reported its financial results for the third quarter and nine months ended September 30, 2006."
08/09/2006 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Second Quarter and Six-month Financial and Operational Results Wellesley, MA, August 9, 2006 - Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, today reported its financial results for the second quarter and six months ended June 30, 2006."
05/11/2006 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports First Quarter Financial Results"
02/23/2006 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Fourth Quarter and Full Year 2005 Financial Results Wellesley, MA, February 23, 2006—Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, today reported its financial results for the quarter and year ended December 31, 2005. The Company also provided full year 2006 financial guidance.",
"Coley Pharmaceutical Group Initiates Phase II Clinical Study of Actilon™ for Hepatitis C"
11/14/2005 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Third Quarter Financial Results Wellesley, MA, November 10, 2005—Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics ™ , today reported its financial results for the third quarter ended September 30, 2005. The company reported revenue of $4.9 million for the third quarter compared to $2.1 million for the same period last year. This increase was primarily due to revenue recognized under Coley's licensing agreement with Pfizer Inc., which was entered into earlier in 2005. Coley reported a net loss attributable to common shareholders for the third quarter of 2005 of $10.8 million versus $9.8 million for the third quarter of 2004. Research and development expenses..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy